CNS Embryonal Tumors (Medulloblastoma): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

CNS embryonal tumors are highly malignant pediatric brain tumors arising from primitive neuroectodermal cells. Medulloblastoma is by far the most common, accounting for approximately 20% of all pediatric brain tumors, with an incidence of approximately 0.5 per 100,000 children per year. It arises predominantly in the posterior fossa cerebellar vermis in children aged 3–8 years, with a second smaller peak in adults aged 25–35. The WHO 2021 classification integrates histological and molecular criteria, defining four molecular subgroups with distinct biology, clinical behavior, and prognosis: WNT-activated, SHH-activated, Group 3, and Group 4. Other rare CNS embryonal tumors include CNS embryonal tumor with multilayered rosettes (ETMR, formerly ependymoblastoma/ETANTR), atypical teratoid/rhabdoid tumor (AT/RT, characterized by SMARCB1/SMARCA4 loss), and CNS neuroblastoma. These tumors frequently disseminate through the cerebrospinal fluid (leptomeningeal spread), requiring whole neuraxis staging and treatment.

Most medulloblastomas arise sporadically without identified cause. Germline mutations predisposing to specific molecular subgroups include PTCH1 mutations (Gorlin syndrome, associated with SHH-activated medulloblastoma), TP53 mutations (Li-Fraumeni syndrome, associated with SHH tumors with poor outcomes), and APC mutations (Turcot syndrome, predisposing to WNT-activated subgroup). The four molecular subgroups have distinct somatic driver events: WNT subgroup — CTNNB1 activating mutations and chromosome 6 monosomy; SHH subgroup — PTCH1, SMO, SUFU mutations or GLI2 amplification; Group 3 — MYC amplification (worst prognosis driver); Group 4 — SNCAIP duplication and CDK6 amplification. Ionizing radiation exposure is a rare recognized environmental risk factor. Prior cranial irradiation for other childhood cancers increases secondary CNS tumor risk.

Posterior fossa tumors classically cause obstructive hydrocephalus from blockage of CSF flow at the fourth ventricle, leading to increased intracranial pressure. Presenting symptoms include early-morning headache (worse on waking, often with vomiting), nausea, and papilledema on fundoscopy. Cerebellar involvement produces truncal ataxia (unsteady gait, frequent falls), appendicular dysmetria (incoordination of limb movements), dysarthria, and nystagmus. Diplopia and facial weakness indicate brainstem infiltration. Symptoms typically evolve subacutely over 2–6 months before diagnosis. Spinal leptomeningeal metastases cause back pain, lower limb weakness, or bowel or bladder dysfunction. In infants, bulging fontanelle and rapid head circumference growth are early signs. Symptoms of CNS Embryonal Tumors (Medulloblastoma): Causes, Symptoms, Diagnosis and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

MRI of the entire brain and spinal cord with gadolinium contrast is mandatory before surgery to characterize the primary tumor and detect leptomeningeal spread. The posterior fossa tumor typically appears as an enhancing midline mass originating in the cerebellar vermis with T1-hypointense and T2-hyperintense signal. CSF cytology for tumor cells is obtained from lumbar puncture at least 14 days after surgery to avoid false positives from surgical blood contamination. Histopathology with H&E identifies histological subtypes (classic, desmoplastic/nodular, large-cell/anaplastic, MBEN). Molecular profiling — IHC for beta-catenin (WNT), GAB1/SFRP1 (SHH), versus Group 3/4 — is required; DNA methylation array (Heidelberg classifier) provides definitive molecular classification. Chang M-staging classifies metastatic disease (M0–M4).

Maximal safe surgical resection is the essential first step; gross total or near-total resection is associated with improved survival. Residual tumor volume greater than 1.5 cm2 defines high-risk disease. Children over age 3 with standard-risk disease (no or minimal residual tumor, M0) receive 23.4 Gy craniospinal irradiation plus 54–55.8 Gy posterior fossa boost, followed by adjuvant maintenance chemotherapy with vincristine, lomustine (CCNU), and cisplatin for 8 cycles. High-risk disease (metastatic, M1–M4, or residual disease) receives 36 Gy CSI with chemotherapy. Children under age 3 receive high-dose multi-agent chemotherapy with thiotepa and autologous stem cell rescue to delay radiation. WNT-activated medulloblastoma trials are evaluating reduced-intensity CSI (18 Gy) given its excellent prognosis. SHH-activated tumors are being studied with hedgehog pathway inhibitors (vismodegib in adults, investigational in pediatrics).

WNT-activated medulloblastoma: 5-year event-free survival (EFS) exceeds 95%, the best prognosis of all subgroups. SHH-activated standard-risk: approximately 70% 5-year EFS; TP53-mutant SHH carries the worst prognosis within this subgroup. Group 3 (especially metastatic, MYC-amplified): less than 30% 5-year survival. Group 4: approximately 70–80% 5-year EFS. Overall pediatric medulloblastoma 5-year survival is 65–75%. Long-term neurocognitive and endocrine late effects — including IQ decline, growth hormone deficiency, and secondary cancers — are major concerns requiring dedicated long-term follow-up programs. The prognosis for CNS Embryonal Tumors (Medulloblastoma): Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

No known environmental exposures are established as preventable causes of sporadic medulloblastoma. Genetic testing for Gorlin syndrome (PTCH1), Li-Fraumeni syndrome (TP53), and Turcot syndrome (APC) is recommended for patients with medulloblastoma who have family history of these conditions, younger age at onset, or specific histological subtype patterns (desmoplastic MF suggests SHH pathway predisposition). Carriers of germline PTCH1 or TP53 mutations should undergo annual brain MRI and clinical surveillance. Minimizing unnecessary cranial radiation in children receiving treatment for other cancers reduces secondary CNS tumor risk. Patients with AT/RT should be tested for germline SMARCB1 mutations, which can predict familial rhabdoid tumor predisposition requiring family screening.

Seek urgent neurological evaluation for any child with persistent or progressive early-morning headaches, recurrent unexplained vomiting (especially in the morning without nausea or fever), unsteady gait or frequent falls, new difficulties with coordination, unexplained squinting or double vision, or a change in handwriting or school performance. These symptoms may be subtle and may initially mimic common conditions — any persistence beyond 2–4 weeks in a child requires brain imaging. In infants, a rapidly enlarging head circumference, a tense or bulging fontanelle, unexplained irritability, or developmental regression should prompt immediate evaluation. Emergency care is required for severe headache with vomiting, altered consciousness, or sudden neurological deterioration, which may indicate acute hydrocephalus requiring urgent neurosurgical intervention.